newsfilter
← Latest News
PR Newswire·

BiondVax and European Investment Bank sign definitive amendment extending maturity of loan until December 2027 with additional terms in support of BiondVax's new strategy

JERUSALEM, Aug. 10, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative biological medicinal products for the prevention and treatment of infe